Mergers & Acquisitions
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 13–24 of 64 articles
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
STAT+ R&D Performance Ranking: Insights for Pharma Companies
Structured plan for STAT+ R&D Performance Ranking: Insights for Pharma Companies
TrumpRx's Generic Drug Expansion: Strategic Implications for the Pharmaceutical Industry
TrumpRx's strategic expansion into the generic drug market presents a significant shift, potentially altering pricing dynamics and competitive landscapes. This analysis explores the critical implications for pharmaceutical business development, regulatory affairs, and investment strategies.
Eli Lilly and Ascidian Therapeutics Forge RNA Exon Editing Alliance for Genetic Kidney Diseases
Eli Lilly has entered a significant research collaboration with Ascidian Therapeutics, aiming to develop novel RNA exon editing therapeutics for genetic kidney diseases. The deal highlights the growing interest in RNA-based therapies and Ascidian's innovative exon editing technology.
Opinion: How the military may be fueling eating disorders in men
Structured plan for Opinion: How the military may be fueling eating disorders in men
Sun Pharma and Organon File HSR, Awaiting Antitrust Clearance
Sun Pharmaceuticals and Organon & Co. have submitted their Hart-Scott-Rodino premerger notification, with the antitrust waiting period scheduled to expire on June 22. This filing marks a significant step in their potential transaction.
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics has announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership within the biotech sector.
Vyome Holdings Q1 2026: FDA Filings and Financial Strength Signal Strategic Momentum
Vyome Holdings announced its first quarter 2026 financial results, underscoring significant progress with key FDA filings and a strengthened balance sheet. The company's performance indicates a strategic focus on regulatory advancement and financial stability.
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing
Structured plan for Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing
Duchesnay Pharmaceutical Group's Growth Trajectory Five Years Post-Acquisition
Five years after its acquisition by senior management in 2021, Duchesnay Pharmaceutical Group (DPG) has achieved significant and sustained growth across sales, exports, and employment. This expansion solidifies DPG's standing as one of Canada's few comprehensive pharmaceutical businesses.
OhioHealth and Fairfield Medical Center Terminate Merger Plans
OhioHealth and Fairfield Medical Center have officially terminated their proposed merger plans, a development that alters the landscape of healthcare provider news in Ohio. The initial announcement of the acquisition proposal was made last November.
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.